NTP study supports safety of chromium pico

28 September 2008

US supplements giant Nutrition 21 says study results released by the National Toxicology Program support the safety of short-term and long-term use of chromium picolinate. Multiple safety trial were performed in animals, including a two-year study using daily doses of chromium picolinate equivalent to 50,000 times the common human dose found in supplements.

Michael Zeher, chief executive of Nutrition 21, said: "over the years, Chromax chromium picolinate has proven to be an efficacious compound in assisting consumers to safely and proactively attain, and maintain, healthy blood glucose levels, carbohydrate metabolism and body composition."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight